Severe infections in patients with autoimmune diseases treated with cyclophosphamide;Infecciones graves en pacientes con enfermedades autoinmunes tratados con ciclofosfamida

Reumatologia Clinica

Volumn 11, Issue 4, 2015, Pages 221-223

  Cavallasca, Javier A ^a   Costa, Cecilia A ^a   Maliandi, Maria del Rosario ^a   Contini, Liliana E ^a   Fernandez de Carrera, Elena ^a   Musuruana, Jorge L ^a  

^a Hospital JBIturraspe Santa Fe   (Argentina)

Author keywords

Connective tissue diseases; Corticosteroids; Cyclophosphamide; Infections,Immunosuppressive drugs

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AUTOIMMUNE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DOSE RESPONSE; DRUG SAFETY; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PROLIFERATIVE GLOMERULONEPHRITIS; RETROSPECTIVE STUDY; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; AGED; AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; CROSS-SECTIONAL STUDY; FEMALE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; CROSS-SECTIONAL STUDIES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84931827836     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2014.09.003     Document Type: Article

References (11)

1. Juárez M., Misischia R., Alarcón G.S. Infections in systemic connective tissue diseases: Systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am. 2003, 29:163-184.
2. Miller A.V., Ranatunga S.K. Immunotherapies in rheumatologic disorders. Med Clin North Am. 2012, 96:475-496.
3. Altman D. Practical statistics for medical research 1991, Chapman and Hall, London.
4. Fauci A.S., Haynes B.F., Katz P., Wolff S.M. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983, 98:76-85.
5. Austin H.A., Klippel J.H., Balow J.E., le Riche N.G., Steinberg A.D., Plotz P.H., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986, 314:614-619.
6. Martin F., Lauwerys B., Lefèbvre C., Devogelaer J.P., Houssiau F.A. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus. 1997, 6:254-257.
7. Haga H.J., D'Cruz D., Asherson R., Hughes G.R. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis. 1992, 51:885-888.
8. Martin-Suarez I., D'Cruz D., Mansoor M., Fernandes A.P., Khamashta M.A., Hughes G.R. Immunosuppressive treatment in severe connective tissue diseases: Effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997, 56:481-487.
9. a ed. S. Ruddy, E.D. Harris, C.B. Sledge (Eds.).
10. Pryor B.D., Bologna S.G., Kahl L.E. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996, 39:1475-1482. Erratum in: Arthritis Rheum. 1997;40:1711.
11. Fardet L., Kassar A., Cabane J., Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf. 2007, 30:861-881.